Analysis of tamoxifen and its main metabolites in plasma samples of breast cancer survivor female athletes: Multivariate and chemometric optimization

• Published in: Journal of separation science 2022-04, Vol.45 (7), p.1362-1373
• Main Authors: Sadeghcheh, Tahereh, Saber Tehrani, Mohammad, Faraji, Hakim, Aberoomand Azar, Parviz, Helalizadeh, Masoumeh
• Format: Article
• Language: English
• Subjects: Analytical chemistry; Blood plasma; Breast cancer; Breast Neoplasms - drug therapy; Cancer Survivors; Chemometrics; Chromatography, High Pressure Liquid - methods; Deep Eutectic Solvents; dispersive liquid‐liquid microextraction; Female; female athletes; Humans; Independent variables; Limit of Detection; Liquid chromatography; Liquid Phase Microextraction - methods; Metabolites; Multivariate analysis; Optimization; Pharmacology; Plasma; Solvents; Solvents - chemistry; Tamoxifen
• ISSN: 1615-9306; 1615-9314
• DOI: 10.1002/jssc.202100899

A sensitive method based on liquid chromatography combined with a diode array detector was developed and validated to simultaneously determine tamoxifen, and its active metabolites N‐desmethyltamoxifen, 4‐hydroxytamoxifen, and endoxifen in human plasma samples. The green and sustainable vortex‐assisted dispersive liquid‐phase microextraction technique based on the natural hydrophobic deep eutectic solvent was used for the extraction and preconcentration of the analytes. Chemometrics and multivariate analysis were used to optimize the independent variables including the type and volume of deep eutectic solvent, extraction time, and ionic strength. Under optimal conditions, calibration curves were linear in a suitable range with the lower limits of quantification (0.8–10.0 μg/L), which covered the relevant concentrations of the analytes in plasma samples for a clinical study. Intra‐ and interday precision evaluated at three concentrations for the analytes were lower than 8.2 and 12.1%, respectively. Accuracy was in the range of 94.9–104.7%. The applicability of the developed method on human plasma samples illustrated the range 45.1–72.8, 98.4–128.3, 0.9–1.2, and 2.7–6.1 μg/L for tamoxifen, N‐desmethyltamoxifen, 4‐hydroxytamoxifen, and endoxifen, respectively. The validated method can be effective for the pharmacokinetics, pharmacodynamics, and therapeutic drug monitoring studies of tamoxifen and its main metabolites in biological fluids.